Spruce Street Capital LP, along with co-Managing Partners Alex R. Rosen and Simon Basseyn, filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 11,213,455 ordinary shares of Entera Bio Ltd. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Spruce Street Capital LP and its associated reporting persons each reported beneficial ownership of 11,213,455 ordinary shares of Entera Bio Ltd.
- Ownership percentage: The reported stake represents 6.4% of the outstanding ordinary shares.
- Shares outstanding basis: The percentage was calculated using 173,922,428 ordinary shares outstanding as of September 18, 2026, as reported in the company's Preliminary Proxy Statement on Schedule 14A filed September 23, 2026.
- Voting and dispositive power: All three reporting persons reported zero sole voting or dispositive power, and 11,213,455 shares each of shared voting and shared dispositive power.
- Key subsidiary disclosed: Spruce Street Capital Master Fund LP is identified as having the right to receive, or the power to direct receipt of, dividends or sale proceeds from more than 5% of the outstanding ordinary shares.
- Triggering event date: The event requiring the filing occurred on September 30, 2026.
Spruce Street Capital's Schedule 13G Filing for Entera Bio Ordinary Shares
According to the filing, Spruce Street Capital LP serves as investment manager to certain investment funds and accounts collectively referred to as the Spruce Street Funds. The Schedule 13G was filed jointly by three reporting persons: Spruce Street Capital LP, Alex R. Rosen, and Simon Basseyn. Rosen and Basseyn are each identified as co-Managing Member of Spruce Street Capital GP LLC, the general partner of the Investment Manager, and as co-Managing Partner of the Investment Manager. The business address for all reporting persons is 777 Third Avenue, Suite 1704, New York, New York 10017.
The filing reports that all 11,213,455 ordinary shares, par value NIS 0.0000769 per share, are held on a shared basis. No reporting person claims sole voting or sole dispositive power over any shares. The 6.4% ownership figure was derived from a total of 173,922,428 ordinary shares outstanding as of September 18, 2026, sourced from Entera Bio's Preliminary Proxy Statement on Schedule 14A. Under Item 6, the filing identifies Spruce Street Capital Master Fund LP as the Spruce Street Fund with the right to receive or the power to direct receipt of dividends or proceeds from sale of more than 5% of the outstanding ordinary shares.
The filing also includes a standard certification under Item 10 stating that, to the best of the reporting persons' knowledge and belief, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." A Joint Filing Agreement is attached as Exhibit 99.1. The filing does not name a specific exchange or ticker symbol for Entera Bio's ordinary shares in the Schedule 13G text itself.
What Was Disclosed
Spruce Street Capital LP and its two co-Managing Partners disclosed a combined beneficial ownership of 11,213,455 ordinary shares of Entera Bio Ltd., equal to 6.4% of the class, all held with shared voting and dispositive power as of September 30, 2026.




Please wait processing your request...